A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies

This study is testing a new, personalized treatment for certain types of blood cancer that are difficult to treat. Researchers are modifying your own immune cells to help them find and attack cancer cells that have specific genetic changes.

You may be eligible if you are between 18 and 75 years old and have been diagnosed with specific blood cancers like leukemia or MDS. Your cancer must have certain genetic markers (TP53 or RAS mutations) and you must have a matching protein type (HLA) to be a candidate.

After a health screening, doctors will collect your immune cells and modify them in a lab. You will receive a short course of chemotherapy to prepare your body, followed by an infusion of your 'reprogrammed' cells and a stay in the clinic for monitoring.

The study is currently recruiting participants at the National Institutes of Health in Bethesda, Maryland. Participation involves long-term follow-up visits to monitor your health over several years.